Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • Inside Hinde Group’s Investment Case for Mobility Global (MBGL)
    • Investors lose faith in bonds as stagflation fears reshape asset allocation
    • Is it finally time to invest in the FTSE 100?
    • How Baron Capital Holds SpaceX Across Its Active ETFs
    • CoreWeave’s $30 Million Insider Bond Bet Comes Amid Debt Fears — TradingView News
    • HSBC Launches Ethereum-Based Money Market Fund
    • Pierce Brosnan sends ‘grá mor’ to Robert Pattinson following Bond reveal
    • ‘I’m 65 and love to travel – will my £1.3m savings fund the rest of my life?’
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Investments»GLP-1s are driving returns on R&D investments for Big Pharma, report says
    Investments

    GLP-1s are driving returns on R&D investments for Big Pharma, report says

    March 25, 2025


    In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. - Image: Mario Tama / Staff (Getty Images)
    In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. – Image: Mario Tama / Staff (Getty Images)

    Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular diabetes drug Ozempic.

    Deloitte’s annual report, Measuring the Return from Pharmaceutical Innovation, found that GLP-1 drugs could fuel significant returns on research and development investments made last year by major drugmakers. The consulting firm analyzed the projected internal rate of return for late-stage pipeline assets across the 20 leading pharma companies.

    On average, these companies forecast peak sales of $510 million per asset. But when GLP-1s are excluded, that figure drops sharply to $370 million. The internal rate of return for late-stage pipeline assets climbed from 5.9% in 2024, from 4.1% in 2023 — again driven in large part by GLP-1 drugs. Without them, returns would have declined, dipping to 3.8% in 2024 and 3.4% in 2023.

    This matters even more given that the report also found that the average cost to develop a drug for Big Pharma was $2.23 billion in 2024, up from $2.12 billion the year before.

    GLP-1 drugs mimic hormones that regulate blood sugar and suppress appetite, making them highly sought after for treating obesity and Type 2 diabetes. The surging demand has propelled Eli Lilly (LLY) and Novo Nordisk into becoming the largest pharma companies in the world. Eli Lilly’s weight-loss drug Zepbound generated $4.9 billion in annual revenue, while Novo Nordisk’s rival treatment, Wegovy, reached roughly $8 billion in sales.

    Wall Street has taken notice. Since the U.S. Food and Drug Administration (FDA) approved Zepbound in November 2023, Eli Lilly’s stock has soared more than 40%, pushing its market capitalization past $750 billion. Novo Nordisk has seen an even steeper climb, with its stock rising over 76% since Wegovy’s launch in 2021.

    With such massive returns, several companies — including Novo Nordisk, Eli Lilly, Pfizer, and Amgen— are advancing next-generation GLP-1 drugs and investigating their potential for new uses, such as treating sleep apnea and improving heart health.

    For the latest news, Facebook, Twitter and Instagram.





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    Inside Hinde Group’s Investment Case for Mobility Global (MBGL)

    November 19, 2026

    ‘I’m 65 and love to travel – will my £1.3m savings fund the rest of my life?’

    November 19, 2026

    EBRD and EU strengthen Jordan’s water security

    November 19, 2026
    Leave A Reply Cancel Reply

    Top Posts

    Scofflaw property investors sued for $2.2 million : Investigative Post

    November 19, 2026

    Investors lose faith in bonds as stagflation fears reshape asset allocation

    November 19, 2026

    Inside Hinde Group’s Investment Case for Mobility Global (MBGL)

    November 19, 2026

    2 ETFs to Watch for Outsized Volume on European Equities & Bonds

    November 19, 2026
    Don't Miss
    Investments

    Inside Hinde Group’s Investment Case for Mobility Global (MBGL)

    November 19, 2026

    Hinde Group, an investment management company, has released its third-quarter 2026 investor letter. The portfolio…

    Investors lose faith in bonds as stagflation fears reshape asset allocation

    November 19, 2026

    Is it finally time to invest in the FTSE 100?

    November 19, 2026

    How Baron Capital Holds SpaceX Across Its Active ETFs

    November 19, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Lombard Odier & Cie s’associe à BlueBay pour lancer un fonds sur les obligations souveraines

    July 2, 2025

    Gold ETFs Winning the Asset Race With Bitcoin Funds–for Now

    March 14, 2025

    Real estate tokenisation « Euro Weekly News

    February 18, 2025
    Our Picks

    Inside Hinde Group’s Investment Case for Mobility Global (MBGL)

    November 19, 2026

    Investors lose faith in bonds as stagflation fears reshape asset allocation

    November 19, 2026

    Is it finally time to invest in the FTSE 100?

    November 19, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    🇮🇸 CPP Investments and Equinix complete atNorth acquisition to support growth of leading Nordic data center platform

    September 1, 2026
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.